English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Small cell lung cancer (SCLC) is an invasive and high-grade neuroendocrine malignant tumor. It is characterized by short doubling time, high proliferation rate, and early extensive metastasis. SCLC is sensitive to radiotherapy and chemotherapy in the initial stage; however, it can easily relapse and develop drug resistance. In the past five years, there has been a resurgence of research on SCLC worldwide, including the establishment of SCLC cells, the development of related genetically engineered mouse models (GEMMs) and the establishment of patient-derived xenograft models (PDXs). These studies have identified new potential therapeutic vulnerabilities for SCLC, leading to new clinical trials. In this perspective, the establishment, application, and advantages and disadvantages of three preclinical research models of SCLC are systematically summarized.

Advances in Preclinical Models of Small Cell Lung Cancer